Tarsus Pharmaceuticals Analyst Ratings
Tarsus Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 146.91% | HC Wainwright & Co. | $50 → $42 | Maintains | Buy |
| 07/26/2023 | 193.94% | HC Wainwright & Co. | $44 → $50 | Maintains | Buy |
| 07/18/2023 | 158.67% | William Blair | → $44 | Initiates Coverage On | → Outperform |
| 06/26/2023 | 158.67% | HC Wainwright & Co. | $40 → $44 | Maintains | Buy |
| 06/16/2023 | 146.91% | Guggenheim | $40 → $42 | Maintains | Buy |
| 05/18/2023 | — | Guggenheim | Initiates Coverage On | → Buy | |
| 05/08/2023 | 152.79% | Oppenheimer | → $43 | Reiterates | → Outperform |
| 03/15/2023 | 135.16% | HC Wainwright & Co. | → $40 | Reiterates | → Buy |
| 08/01/2022 | 135.16% | Barclays | → $40 | Initiates Coverage On | → Overweight |
| 12/21/2021 | 135.16% | HC Wainwright & Co. | → $40 | Initiates Coverage On | → Buy |
| 11/23/2021 | 223.34% | Oppenheimer | → $55 | Initiates Coverage On | → Outperform |
| 10/08/2021 | 282.13% | Raymond James | $50 → $65 | Maintains | Strong Buy |
| 06/29/2021 | 193.94% | Raymond James | $39 → $50 | Maintains | Strong Buy |
| 11/10/2020 | 146.91% | Ladenburg Thalmann | → $42 | Initiates Coverage On | → Buy |
| 11/10/2020 | 94% | B of A Securities | → $33 | Initiates Coverage On | → Buy |
| 11/10/2020 | 105.76% | Jefferies | → $35 | Initiates Coverage On | → Buy |
| 11/10/2020 | 129.28% | Raymond James | → $39 | Initiates Coverage On | → Strong Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/11/2023 | 146.91% | HC Wainwright & Co. | 50 美元 → 42 美元 | 維護 | 購買 |
| 07/26/2023 | 193.94% | HC Wainwright & Co. | 44 美元 → 50 美元 | 維護 | 購買 |
| 07/18/2023 | 158.67% | 威廉布萊爾 | → 44 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 06/26/2023 | 158.67% | HC Wainwright & Co. | 40 美元 → 44 美元 | 維護 | 購買 |
| 06/16/2023 | 146.91% | 古根海姆 | 40 美元 → 42 美元 | 維護 | 購買 |
| 05/18/2023 | — | 古根海姆 | 啓動覆蓋開啓 | → 購買 | |
| 05/08/2023 | 152.79% | 奧本海默 | → 43 美元 | 重申 | → 跑贏大盤 |
| 03/15/2023 | 135.16% | HC Wainwright & Co. | → 40 美元 | 重申 | → 購買 |
| 08/01/2022 | 135.16% | 巴克萊 | → 40 美元 | 啓動覆蓋開啓 | → 超重 |
| 2021 年 12 月 21 日 | 135.16% | HC Wainwright & Co. | → 40 美元 | 啓動覆蓋開啓 | → 購買 |
| 11/23/2021 | 223.34% | 奧本海默 | → 55 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 2021 年 8 月 10 日 | 282.13% | 雷蒙德·詹姆 | 50 美元 → 65 美元 | 維護 | 強勢買入 |
| 06/29/2021 | 193.94% | 雷蒙德·詹姆 | 39 美元 → 50 美元 | 維護 | 強勢買入 |
| 11/10/2020 | 146.91% | 拉登堡塔爾曼 | → 42 美元 | 啓動覆蓋開啓 | → 購買 |
| 11/10/2020 | 94% | B of A 類證券 | → 33 美元 | 啓動覆蓋開啓 | → 購買 |
| 11/10/2020 | 105.76% | 傑富瑞 | → 35 美元 | 啓動覆蓋開啓 | → 購買 |
| 11/10/2020 | 129.28% | 雷蒙德·詹姆 | → 39 美元 | 啓動覆蓋開啓 | → 強勢買入 |
What is the target price for Tarsus Pharmaceuticals (TARS)?
Tarsus Pharmicals（TARS）的目標價格是多少？
The latest price target for Tarsus Pharmaceuticals (NASDAQ: TARS) was reported by HC Wainwright & Co. on August 11, 2023. The analyst firm set a price target for $42.00 expecting TARS to rise to within 12 months (a possible 146.91% upside). 8 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年8月11日公佈了Tarsus Pharmicals（納斯達克股票代碼：TARS）的最新目標股價。這家分析公司將目標股價定爲42.00美元，預計TARS將在12個月內升至146.91％（可能上漲146.91％）。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for Tarsus Pharmaceuticals (TARS)?
Tarsus Pharmicals（TARS）的最新分析師評級是多少？
The latest analyst rating for Tarsus Pharmaceuticals (NASDAQ: TARS) was provided by HC Wainwright & Co., and Tarsus Pharmaceuticals maintained their buy rating.
Tarsus Pharmicals（納斯達克股票代碼：TARS）的最新分析師評級由HC Wainwright & Co. 提供，Tarsus Pharmicals維持買入評級。
When is the next analyst rating going to be posted or updated for Tarsus Pharmaceuticals (TARS)?
Tarsus Pharmicals（TARS）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tarsus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tarsus Pharmaceuticals was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Tarsus Pharmicals的高管和客戶交談以及聽取業績電話會議）後得出了股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Tarsus Pharmicals的最新評級是在2023年8月11日提交的，因此您應該預計下一個評級將在2024年8月11日左右公佈。
Is the Analyst Rating Tarsus Pharmaceuticals (TARS) correct?
分析師對Tarsus Pharmicals（TARS）的評級正確嗎？
While ratings are subjective and will change, the latest Tarsus Pharmaceuticals (TARS) rating was a maintained with a price target of $50.00 to $42.00. The current price Tarsus Pharmaceuticals (TARS) is trading at is $17.01, which is out of the analyst's predicted range.
儘管評級是主觀的，將會發生變化，但最新的Tarsus Pharmicals（TARS）評級維持不變，目標股價爲50.00美元至42.00美元。Tarsus Pharmicals（TARS）目前的交易價格爲17.01美元，超出了分析師的預測區間。